Clinical Trials Of Neoadjuvant Targeted Therapy In Resectable Nsclc

Clinical trials of neoadjuvant targeted therapy in resectable NSCLC

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLC

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

Touch Medical Media

Will neoadjuvant targeted therapies play a role in NSCLC?

Maximizing the Impact of EGFR-Targeted Therapy in Resectable NSCLC

PeerView Oncology

Surgical perspective on neoadjuvant IO for resectable stage III NSCLC

8 in 8 Series: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC

ThoracicSurgeons

NAUTIKA1: targeted therapies in biomarker-selected stage IB-II NSCLC

Selecting patients with NSCLC who benefit from immunotherapy or targeted therapies

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091

Neoadjuvant EGFR TKI trials in NSCLC

Precision Oncology in Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way

PeerView Oncology

Advances in Immunotherapy & Resectable Non-Small Cell Lung Cancer

MedStar Georgetown Department of Medicine

NAUTIKA1: safety and tolerability of neoadjuvant alectinib in ALK-positive NSCLC

Advancements in targeted therapies for oncogene-driven resectable NSCLC

Response and safety profile of neoadjuvant nivolumab for resectable lung cancer

Lung Cancer Clinical Trials: Edward's Story

American Lung Association

Immunotherapy as combination and neoadjuvant therapies in NSCLC

Achieving textbook outcomes with neoadjuvant targeted therapy in borderline resectable melanoma

S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy